CN115551534A - 一种预防和治疗血压异常病症的方法和药物 - Google Patents
一种预防和治疗血压异常病症的方法和药物 Download PDFInfo
- Publication number
- CN115551534A CN115551534A CN202180012694.9A CN202180012694A CN115551534A CN 115551534 A CN115551534 A CN 115551534A CN 202180012694 A CN202180012694 A CN 202180012694A CN 115551534 A CN115551534 A CN 115551534A
- Authority
- CN
- China
- Prior art keywords
- plasminogen
- blood pressure
- mice
- plasmin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种治疗血压异常病症的方法，包括给药受试者有效量的纤维蛋白溶酶原激活途径组分。本发明还涉及治疗血压异常病症的药物和制品及其用途。
Description
PCT国内申请，说明书已公开。
Claims (18)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010119730 | 2020-02-26 | ||
| CN2020101197309 | 2020-02-26 | ||
| PCT/CN2021/078200 WO2021170099A1 (zh) | 2020-02-26 | 2021-02-26 | 一种预防和治疗血压异常病症的方法和药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115551534A true CN115551534A (zh) | 2022-12-30 |
Family
ID=77490734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180012694.9A Pending CN115551534A (zh) | 2020-02-26 | 2021-02-26 | 一种预防和治疗血压异常病症的方法和药物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230139956A1 (zh) |
| EP (1) | EP4112069A4 (zh) |
| JP (1) | JP2023514819A (zh) |
| KR (1) | KR20220143913A (zh) |
| CN (1) | CN115551534A (zh) |
| CA (1) | CA3169325A1 (zh) |
| TW (1) | TW202140067A (zh) |
| WO (1) | WO2021170099A1 (zh) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US20030125233A1 (en) * | 2000-06-27 | 2003-07-03 | Peter Carmeliet | Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling |
| US20120027558A1 (en) * | 2010-07-28 | 2012-02-02 | Weeden Todd M | Tire storage system |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| CA3008186A1 (en) * | 2015-12-18 | 2017-06-22 | Talengen International Limited | Novel method for preventing and treating angiocardiopathy |
| CN106890320A (zh) * | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| US11090372B2 (en) * | 2015-12-18 | 2021-08-17 | Talengen International Limited | Method of treating diabetic nephropathy comprising administering plasminogen |
| CN105535950A (zh) * | 2016-02-02 | 2016-05-04 | 武汉真福医药股份有限公司 | 制备纤溶酶组合物的方法及其应用 |
| CN110167583A (zh) * | 2016-12-15 | 2019-08-23 | 泰伦基国际有限公司 | 一种治疗冠状动脉粥样硬化及其并发症的方法 |
| CN108210893A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗肾纤维化的药物及其用途 |
| CN108210909A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗脂质肾损伤的药物及其用途 |
| CN108210905A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗皮肤纤维化的药物及其用途 |
| CN108210917A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
| CN108210895A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防动脉粥样硬化及其并发症的药物及其用途 |
| CN108210915A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 改善心脏病变的药物及其用途 |
| CN109125715A (zh) * | 2017-06-19 | 2019-01-04 | 深圳瑞健生命科学研究院有限公司 | 一种调控glp-1/glp-1r的方法和药物 |
-
2021
- 2021-02-26 CN CN202180012694.9A patent/CN115551534A/zh active Pending
- 2021-02-26 EP EP21760438.8A patent/EP4112069A4/en active Pending
- 2021-02-26 KR KR1020227032536A patent/KR20220143913A/ko active Search and Examination
- 2021-02-26 TW TW110107105A patent/TW202140067A/zh unknown
- 2021-02-26 CA CA3169325A patent/CA3169325A1/en active Pending
- 2021-02-26 US US17/802,280 patent/US20230139956A1/en active Pending
- 2021-02-26 WO PCT/CN2021/078200 patent/WO2021170099A1/zh unknown
- 2021-02-26 JP JP2022548090A patent/JP2023514819A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202140067A (zh) | 2021-11-01 |
| US20230139956A1 (en) | 2023-05-04 |
| WO2021170099A1 (zh) | 2021-09-02 |
| EP4112069A1 (en) | 2023-01-04 |
| CA3169325A1 (en) | 2021-09-02 |
| JP2023514819A (ja) | 2023-04-11 |
| KR20220143913A (ko) | 2022-10-25 |
| EP4112069A4 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11090372B2 (en) | Method of treating diabetic nephropathy comprising administering plasminogen | |
| CA3008694C (en) | Use of plasminogen for preventing or treating diabetic nerve injury and related disorders thereof | |
| EP3395359A1 (en) | Method for preventing or treating acute thrombosis and chronic thrombosis | |
| JP6783870B2 (ja) | 心血管病を予防及び治療するための新しい方法 | |
| TWI752044B (zh) | 一種預防和治療組織器官纖維化的方法 | |
| CA3008691A1 (en) | Method for preventing or treating diabetic retinopathy | |
| CA3047181A1 (en) | Method and drug for preventing and treating obesity | |
| CN116490200A (zh) | 一种提高ngf水平的方法和药物 | |
| EP4112069A1 (en) | Method and drug for preventing and treating abnormal blood pressure condition | |
| EP4091621A1 (en) | Method for treatment of nerve injury and related disease | |
| EP4190911A1 (en) | Method and drug for tumor treatment | |
| EP4094776A1 (en) | Method and drug for treating viral pneumonia | |
| TW202228766A (zh) | 一種治療神經損傷及其相關病症的方法 | |
| CN113795274A (zh) | 一种治疗肌萎缩侧索硬化的方法和药物 | |
| CN111905103A (zh) | 一种治疗肌萎缩侧索硬化的方法和药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |